0DPB.LSE Bavarian Nordic A/S

Healthcare Commercial Services & Supplies London Exchange
- DKK
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.

Is 0DPB.LSE undervalued?

Graham number

The Graham number of Bavarian Nordic A/S cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bavarian Nordic A/S fundamental analysis

No fundamental analysis for Bavarian Nordic A/S yet.

Bavarian Nordic A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN …

Full company profile